Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
Feng Xu, Ahmad Awada, Rámón Colomer, Bin Yao, Kenichi Inoue, Lisa A. Carey, Thomas Bachelot, Richard Bryce, Rajendra Badwe, Soo Chin Lee, Ajay Mehta, Suryanarayan V.S. Deo, Sung‐Bae Kim, Alvin Wong, Ron Bose, Georgia Demetriou, Igor Bondarenko, Chanchal Goswami
Abstract
Abstract Importance Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. Objective To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus paclitaxel improves progression-free survival compared with trastuzumab plus paclitaxel in the first-line treatment of recurrent and/or metastatic ERBB2-positive breast cancer. Design, Setting, and Participants In the randomized, controlled, open-label NEfERT-T trial conducted from ...